IN2014MN01469A - - Google Patents
Info
- Publication number
- IN2014MN01469A IN2014MN01469A IN1469MUN2014A IN2014MN01469A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A IN 1469MUN2014 A IN1469MUN2014 A IN 1469MUN2014A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A
- Authority
- IN
- India
- Prior art keywords
- derivative
- modulation
- processes
- formula
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to spiro derivative of formula (I) to the use of said derivative in treating diseases and conditions mediated by modulation of voltage gated sodium channels to compositions containing said derivative and processes for its preparation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579613P | 2011-12-22 | 2011-12-22 | |
GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01469A true IN2014MN01469A (en) | 2015-04-17 |
Family
ID=45572877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1469MUN2014 IN2014MN01469A (en) | 2011-12-22 | 2012-12-21 |
Country Status (18)
Country | Link |
---|---|
US (3) | US9376436B2 (en) |
EP (2) | EP2794612B1 (en) |
JP (2) | JP2015502394A (en) |
KR (1) | KR20140113692A (en) |
CN (1) | CN104271581B (en) |
AU (1) | AU2012356386A1 (en) |
BR (1) | BR112014014940A2 (en) |
CA (1) | CA2858938C (en) |
EA (1) | EA026500B1 (en) |
ES (1) | ES2581327T3 (en) |
GB (1) | GB201122113D0 (en) |
HK (2) | HK1203492A1 (en) |
IL (1) | IL233215A0 (en) |
IN (1) | IN2014MN01469A (en) |
MX (1) | MX2014007637A (en) |
SG (1) | SG11201403356YA (en) |
WO (2) | WO2013093497A1 (en) |
ZA (1) | ZA201404269B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
RU2650523C1 (en) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Derivative pyridoxin for treatment of epilepsy |
CN111526874A (en) * | 2017-10-10 | 2020-08-11 | 生物基因公司 | Process for the preparation of spiro derivatives |
EP3651747A4 (en) | 2017-11-17 | 2020-07-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
CN113563258A (en) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | Preparation method of 4-bromo-2- (difluoromethyl) -5-methylpyridine |
WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
CZ293211B6 (en) | 1995-02-13 | 2004-03-17 | G. D. Searle & Co. Corporate Patent Dept. | Substituted isoxazoles for treating inflammations |
UA57002C2 (en) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment |
EP0892791B1 (en) | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
PL187848B1 (en) | 1996-07-18 | 2004-10-29 | Merck Frosst Canada Inc | Substituted pyridines as selective inhibitors of cyclooxygenase-2 |
CO4960662A1 (en) | 1997-08-28 | 2000-09-25 | Novartis Ag | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES |
KR100382619B1 (en) | 1997-09-05 | 2003-05-09 | 글락소 그룹 리미티드 | 2,3-Diaryl-Pyrazolo[1,5-B]Pyridazines Derivatives, Their Preparation and Their Use As Cyclooxygenase 2(COX-2) Inhibitors |
KR20010075673A (en) | 1998-11-03 | 2001-08-09 | 그레이엄 브레레톤, 레슬리 에드워즈 | Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
AU2661400A (en) | 1999-02-27 | 2000-09-21 | Glaxo Group Limited | Pyrazolopyridines |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
SE0302811D0 (en) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
WO2007042250A1 (en) | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
EA200970706A1 (en) | 2007-01-24 | 2010-02-26 | Глэксо Груп Лимитед | NEW PHARMACEUTICAL COMPOSITIONS |
GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
SI2477964T1 (en) | 2009-09-14 | 2015-10-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
MY165579A (en) * | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/en unknown
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/en active Pending
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/en active Active
- 2012-12-21 US US14/365,372 patent/US9376436B2/en active Active
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/en not_active Application Discontinuation
- 2012-12-21 EA EA201491251A patent/EA026500B1/en unknown
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en active Active
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en active Application Filing
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/en active Active
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/en active Pending
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en active Application Filing
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/en not_active Application Discontinuation
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en active Active
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2015
- 2015-04-23 HK HK15103930.0A patent/HK1203492A1/en unknown
- 2015-04-28 HK HK15104075.3A patent/HK1203501A1/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9303032B2 (en) | 2016-04-05 |
US20160185758A1 (en) | 2016-06-30 |
EP2794612A1 (en) | 2014-10-29 |
US9376436B2 (en) | 2016-06-28 |
WO2013093496A1 (en) | 2013-06-27 |
SG11201403356YA (en) | 2014-07-30 |
KR20140113692A (en) | 2014-09-24 |
EP2797922A1 (en) | 2014-11-05 |
CA2858938A1 (en) | 2013-06-27 |
GB201122113D0 (en) | 2012-02-01 |
JP2015502394A (en) | 2015-01-22 |
IL233215A0 (en) | 2014-08-31 |
JP2015502395A (en) | 2015-01-22 |
CA2858938C (en) | 2020-03-10 |
US20140350040A1 (en) | 2014-11-27 |
EA201491251A1 (en) | 2014-11-28 |
ZA201404269B (en) | 2016-06-29 |
HK1203501A1 (en) | 2015-10-30 |
MX2014007637A (en) | 2014-09-26 |
HK1203492A1 (en) | 2015-10-30 |
EA026500B1 (en) | 2017-04-28 |
AU2012356386A1 (en) | 2014-07-10 |
EP2797922B1 (en) | 2016-04-06 |
ES2581327T3 (en) | 2016-09-05 |
US20150225400A1 (en) | 2015-08-13 |
WO2013093497A1 (en) | 2013-06-27 |
CN104271581B (en) | 2016-08-31 |
CN104271581A (en) | 2015-01-07 |
EP2794612B1 (en) | 2016-04-06 |
BR112014014940A2 (en) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502839B1 (en) | Antiviral compounds | |
PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
IN2014MN02459A (en) | ||
MX344530B (en) | Substituted benzene compounds. | |
IN2014MN01469A (en) | ||
EA028156B9 (en) | Fused heterocyclic compounds as ion channel modulators | |
MX369388B (en) | Heterocyclic modulators of lipid synthesis. | |
GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
IN2014MN00988A (en) | ||
MX338916B (en) | Oxazepines as ion channel modulators. | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
JO3773B1 (en) | P2x7 modulators | |
NZ705213A (en) | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | |
IN2015DN01151A (en) | ||
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
IN2014DN06104A (en) | ||
MX2015003701A (en) | Treatment compositions. | |
MX2014002446A (en) | Novel substituted cyclohexane compounds. | |
IN2014MN02393A (en) | ||
IN2015DN00085A (en) | ||
MX347541B (en) | Sialic acid analogs. | |
NZ720807A (en) | Fused heterocyclic compounds as ion channel modulators | |
IN2013MU02279A (en) |